Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Verici Dx Plc ( (GB:VRCI) ) is now available.
Verici Dx reported unaudited FY25 revenues of $3.8m, up from $3.3m in 2024, driven primarily by $3.0m of recognised revenue from its Tutivia™ kidney transplant test and $0.8m in licensing income, while year-end cash of $3.3m and $1.6m in receivables extended its expected cash runway into the second half of 2026. Operationally, the company secured Medicare coverage for Tutivia™, expanded use to 34 centres representing 18% of US annual kidney transplants, grew annual test orders more than threefold to 1,173, and added key commercial agreements with Prime Health Services and Blue Cross Blue Shield of Illinois, positioning Verici Dx for broader US market penetration despite Tutivia™ revenues coming in slightly below market expectations.
The most recent analyst rating on (GB:VRCI) stock is a Hold with a £0.75 price target. To see the full list of analyst forecasts on Verici Dx Plc stock, see the GB:VRCI Stock Forecast page.
Spark’s Take on GB:VRCI Stock
According to Spark, TipRanks’ AI Analyst, GB:VRCI is a Neutral.
Verici Dx Plc’s overall stock score is driven by positive corporate events and technical indicators, which are offset by financial performance challenges and valuation concerns. The company’s strategic initiatives and market expansion efforts are promising, but ongoing profitability and cash flow issues present significant risks.
To see Spark’s full report on GB:VRCI stock, click here.
More about Verici Dx Plc
Verici Dx plc is a UK- and US-headquartered precision diagnostics company focused on transplant care, developing advanced clinical diagnostics that combine multiomic analysis with proprietary artificial intelligence to provide predictive, data-driven insights for clinicians. Its lead product, Tutivia™, is a post-kidney transplant test designed for early detection of acute rejection, supporting therapy optimisation, biopsy guidance and risk stratification across diverse, real-world patient populations.
Average Trading Volume: 1,947,648
Technical Sentiment Signal: Sell
Current Market Cap: £10.97M
For an in-depth examination of VRCI stock, go to TipRanks’ Overview page.